CA4P Combo Treatment Shows Promise in Platinum-Resistant Ovarian Cancer Trial

CA4P Combo Treatment Shows Promise in Platinum-Resistant Ovarian Cancer Trial
An interim analysis from the Phase 2/3 clinical trial assessing Mateon Therapeutics‘ CA4P suggests the drug therapy is safe and effective in platinum-resistant ovarian cancer patients, when used in combination with physician’s choice chemotherapy and Avastin (bevacizumab). “I am encouraged that the safety data is better than we expected and that the efficacy data is

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *